Androgen receptor signaling in androgen-refractory prostate cancer

Journal of the National Cancer Institute

Volumn 93, Issue 22, 2001, Pages 1687-1697

  Grossmann, Michael E ^a   Huang, Haojie ^a   Tindall, Donald J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; CYTOKINE; GROWTH FACTOR; STEROID;

APOPTOSIS; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; HORMONE ACTION; HUMAN; HUMAN CELL; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; RECEPTOR SENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; STANDARD; TUMOR GROWTH; UNITED STATES;

EID: 0035930133     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.22.1687     Document Type: Review

References (128)

1. Carcinoma of the prostate
2. Prostate cancer
3. Cancer statistics, 2000
4. Molecular mechanisms of androgen action
5. Localization of functional domains in the androgen receptor
6. Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators
7. The hallmarks of cancer
8. Growth factor involvement in progression of prostate cancer
9. Prostate cancer: What every man-and his family-needs to know
10. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
11. Androgen receptors in untreated and treated prostatic intraepithelial neoplasia
12. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy
13. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis
14. Androgen receptor status of lymph node metastases from prostate cancer
15. Androgen receptors in endocrine-therapy-resistant human prostate cancer
16. Distant metastases from prostatic carcinoma express androgen receptor protein
17. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer
18. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation
19. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest
20. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar
21. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice
22. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
23. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT
24. Androgen-independent prostate cancer progression in the TRAMP model
25. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer
26. Workgroup 3: Transgenic and reconstitution models of prostate cancer
27. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays
28. Androgen receptor gene and hormonal therapy failure of prostate cancer
29. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells
30. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
31. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer
32. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
33. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
34. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade
35. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia
36. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
37. Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer
38. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
39. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients
40. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer
41. Antiandrogen withdrawal syndrome
42. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer
43. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate
44. The antiandrogen withdrawal syndrome
45. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression
46. Update of the androgen receptor gene mutations database
47. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome
48. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
49. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
50. Regulation of transcription by a protein methyltransferase
51. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins
52. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription
53. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor
54. Cloning and characterization of androgen receptor coactivator ARA54, a novel protein that associates with the androgen receptor
55. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate
56. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells
57. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells
58. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells
59. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
60. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity
61. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
62. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
63. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
64. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice
65. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
66. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation
67. Sex hormong-binding globulin mediates prostate androgen receptor action via a novel signaling pathway
68. Activation of the human androgen receptor through a protein kinase A signaling pathway
69. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
70. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
71. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
72. Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma
73. Cytokine variations in patients with hormone treated prostate cancer
74. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate
75. A tyrosine kinase profile of prostate carcinoma
76. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
77. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma
78. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
79. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
80. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
81. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
82. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer
83. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity
84. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation
85. Androgen receptor interacts with a novel MYST protein, HBO1
86. Cyclin E as a coactivator of the androgen receptor
87. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain
88. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300
89. The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells
90. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells
91. SMAD3 represses androgen receptor-mediated transcription
92. From transforming growth factor-beta signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells
93. Neuroendocrine differentiation in prostatic carcinoma
94. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status
95. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate
96. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells
97. Serotonin as a growth factor
98. Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells
99. Neuropeptides as growth factors. Possible roles in human diseases
100. Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines
101. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2
102. Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells
103. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation
104. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells
105. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells
106. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha
107. Cellular survival: A play in three Akts
108. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
109. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
110. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
111. PTEN: A tumour suppressor that functions as a phospholipid phosphatase
112. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function
113. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
114. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway
115. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells
116. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity
117. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
118. Analysis of PTEN and the 10q23 region in primary prostate carcinomas
119. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
120. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
121. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
122. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells
123. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death
124. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
125. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle
126. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
127. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
128. Bcl-2 alters ligand dependent subcellular distribution of androgen receptor in human prostatic cancer cells